

ASX ANNOUNCEMENT**17 January 2024****Non-Executive Director Resignation**

HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”) advises that Emily Slade has come to the decision to resign as Non-Executive Director of the Company, effective immediately.

The Company would like to thank Emily Slade for her significant contribution and service to the Company since her appointment in 2022.

Dr Ron Weinberger, Chair of HeraMED said “The Board has benefited from Emily’s insights, skills and experience which have supported the ongoing growth of HeraMED. On behalf of the Board, we extend our sincere thanks to and wish Emily every success for the future.”

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited

Executive Chairman

Dr Ron Weinberger

M: +61 406 384 189

E: ron@hera-med.com**Company Secretary**

Jonathan Hart

E: Jonathan@hera-med.com**Investor Relations**

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company’s proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks